These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 8304981)
1. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture. Cory AH; Samano V; Robins MJ; Cory JG Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981 [TBL] [Abstract][Full Text] [Related]
2. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells. Cory AH; Hertel LW; Kroin JS; Cory JG Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives. Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440 [TBL] [Abstract][Full Text] [Related]
4. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model. Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303 [TBL] [Abstract][Full Text] [Related]
5. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells. Weckbecker G; Weckbecker A; Lien EJ; Cory JG J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889 [TBL] [Abstract][Full Text] [Related]
6. Use of nucleoside kinase-deficient mouse leukemia L1210 cell lines to determine metabolic routes of activation of antitumor nucleoside analogs. Cory AH; Cory JG Adv Enzyme Regul; 1994; 34():1-12. PubMed ID: 7942266 [TBL] [Abstract][Full Text] [Related]
7. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Carter GL; Cory JG Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives. Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014 [TBL] [Abstract][Full Text] [Related]
9. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase. Carter GL; Cory JG Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151 [TBL] [Abstract][Full Text] [Related]
10. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cory JG; Carter GL Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399 [TBL] [Abstract][Full Text] [Related]
11. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture. Sato A; Carter GL; Bacon PE; Cory JG Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064 [TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine. Brockman RW; Shaddix SC; Williams M; Nelson JA; Rose LM; Schabel FM Ann N Y Acad Sci; 1975 Aug; 255():501-21. PubMed ID: 171997 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929 [TBL] [Abstract][Full Text] [Related]
15. Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. Wilson JM; Mitchell BS; Daddona PE; Kelley WN J Clin Invest; 1979 Nov; 64(5):1475-84. PubMed ID: 115901 [TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime. Tihan T; Elford HL; Cory JG Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400 [TBL] [Abstract][Full Text] [Related]
17. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants. Johnson CE; Hughes K; Cory JG Cancer Commun; 1991; 3(10-11):341-9. PubMed ID: 1760249 [TBL] [Abstract][Full Text] [Related]
18. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture. Matsumoto M; Tihan T; Cory JG Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572 [TBL] [Abstract][Full Text] [Related]
19. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth. Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487 [TBL] [Abstract][Full Text] [Related]
20. 5-Hexyl-2'-deoxyuridine blocks the cytotoxic effects of 5-fluorodeoxyuridine or deoxyadenosine in leukemia L1210 cells in culture. Cory JG; Halley MC; Jeney A; Lapis K Cancer Res; 1990 Aug; 50(15):4552-6. PubMed ID: 2142444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]